Open access
Sep 2026
Background: Cirrhosis often remains silent until decompensation, after which survival deteriorates sharply. Contemporary, transition-aware estimates are limited, especially in Asian-predominant cohorts. We analyzed trajectories from compensated advanced chronic liver disease (cACLD) through sequential decompensations t...
E. Tan, N. S. Tang, N. Syn et al.
· Hepatology Communications · 0 citations
Save
{ copied = true; setTimeout(() => copied = false, 1500) })"
class="icon-btn" aria-label="Copy link">
{ copied = 'apa'; setTimeout(() => { copied = null; open = false }, 1000) })"
class="flex w-full items-center justify-between rounded-lg px-3 py-2 text-left text-sm hover:bg-gray-100 dark:hover:bg-ink-800">
Copy APA
Copied ✓
{ copied = 'mla'; setTimeout(() => { copied = null; open = false }, 1000) })"
class="flex w-full items-center justify-between rounded-lg px-3 py-2 text-left text-sm hover:bg-gray-100 dark:hover:bg-ink-800">
Copy MLA
Copied ✓
{ copied = 'bibtex'; setTimeout(() => { copied = null; open = false }, 1000) })"
class="flex w-full items-center justify-between rounded-lg px-3 py-2 text-left text-sm hover:bg-gray-100 dark:hover:bg-ink-800">
Copy BibTeX
Copied ✓
Open access
Oct 2026
Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent in patients with type 2 diabetes mellitus (T2DM), yet effective pharmacological options remain limited. Imeglimin, a novel antidiabetic agent targeting mitochondrial bioenergetics, has shown potential hepatoprotective effects in precli...
Kaede Fujita, Takanobu Iwadare, Takefumi Kimura et al.
· Diabetology International · 0 citations
Save
{ copied = true; setTimeout(() => copied = false, 1500) })"
class="icon-btn" aria-label="Copy link">
{ copied = 'apa'; setTimeout(() => { copied = null; open = false }, 1000) })"
class="flex w-full items-center justify-between rounded-lg px-3 py-2 text-left text-sm hover:bg-gray-100 dark:hover:bg-ink-800">
Copy APA
Copied ✓
{ copied = 'mla'; setTimeout(() => { copied = null; open = false }, 1000) })"
class="flex w-full items-center justify-between rounded-lg px-3 py-2 text-left text-sm hover:bg-gray-100 dark:hover:bg-ink-800">
Copy MLA
Copied ✓
{ copied = 'bibtex'; setTimeout(() => { copied = null; open = false }, 1000) })"
class="flex w-full items-center justify-between rounded-lg px-3 py-2 text-left text-sm hover:bg-gray-100 dark:hover:bg-ink-800">
Copy BibTeX
Copied ✓
Open access
Aug 2026
It is shown that ML models integrating biliary-disease associated health records and Gamma glutamyltransferase can stratify risk of future CCA, and demonstrates the potential of data-driven models in personalised screening for hepatobiliary cancer.
F. van Haag, J. Clusmann, Paul-Henry Koop et al.
· EBioMedicine · 0 citations
Save
{ copied = true; setTimeout(() => copied = false, 1500) })"
class="icon-btn" aria-label="Copy link">
{ copied = 'apa'; setTimeout(() => { copied = null; open = false }, 1000) })"
class="flex w-full items-center justify-between rounded-lg px-3 py-2 text-left text-sm hover:bg-gray-100 dark:hover:bg-ink-800">
Copy APA
Copied ✓
{ copied = 'mla'; setTimeout(() => { copied = null; open = false }, 1000) })"
class="flex w-full items-center justify-between rounded-lg px-3 py-2 text-left text-sm hover:bg-gray-100 dark:hover:bg-ink-800">
Copy MLA
Copied ✓
{ copied = 'bibtex'; setTimeout(() => { copied = null; open = false }, 1000) })"
class="flex w-full items-center justify-between rounded-lg px-3 py-2 text-left text-sm hover:bg-gray-100 dark:hover:bg-ink-800">
Copy BibTeX
Copied ✓